Mariya Kronlage1,2,3, Matthias Dewenter1,3, Johannes Grosso1,3, Thomas Fleming4, Ulrike Oehl1,3, Lorenz H Lehmann1,2,3, Inês Falcão-Pires5, Adelino F Leite-Moreira5, Nadine Volk6, Hermann-Josef Gröne7,8, Oliver J Müller2,3, Albert Sickmann9,10,11, Hugo A Katus2,3, Johannes Backs1,3. 1. Institute of Experimental Cardiology (M.K., M.D., J.G., U.O., L.H.L., J.B.), Heidelberg University, Germany. 2. Department of Cardiology (M.K., L.H.L., O.J.M., H.A.K.), Heidelberg University, Germany. 3. German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim (M.K., M.D., J.G., U.O., L.H.L., J.B., L.H.L., O.J.M., H.A.K.). 4. Department of Internal Medicine I (T.F.), Heidelberg University, Germany. 5. Unidade de Investigação Cardiovascular, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Portugal (I.F.-P., A.F.L.-M.). 6. Tissue Bank of the National Center for Tumor Diseases, Heidelberg, Germany (N.V.). 7. Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg (H.-J.G.). 8. Institute of Pathology, University of Marburg, Germany (H.-J.G.). 9. Leibniz Institute for Analysical Sciences (ISAS), Dortmund, Germany (A.S.). 10. Medical Faculty, Medical Proteomics Center, Ruhr-University Bochum, Germany (A.S.). 11. Department of Chemistry, College of Physical Sciences, University of Aberdeen, United Kingdom (A.S.). Dr Müller is currently at the Department of Internal Medicine III, University of Kiel, Germany.
Abstract
BACKGROUND: Worldwide, diabetes mellitus and heart failure represent frequent comorbidities with high socioeconomic impact and steadily growing incidence, calling for a better understanding of how diabetic metabolism promotes cardiac dysfunction. Paradoxically, some glucose-lowering drugs have been shown to worsen heart failure, raising the question of how glucose mediates protective versus detrimental cardiac signaling. Here, we identified a histone deacetylase 4 (HDAC4) subdomain as a molecular checkpoint of adaptive and maladaptive signaling in the diabetic heart. METHODS: A conditional HDAC4 allele was used to delete HDAC4 specifically in cardiomyocytes (HDAC4-knockout). Mice were subjected to diabetes mellitus either by streptozotocin injections (type 1 diabetes mellitus model) or by crossing into mice carrying a leptin receptor mutation (db/db; type 2 diabetes mellitus model) and monitored for remodeling and cardiac function. Effects of glucose and the posttranslational modification by β-linked N-acetylglucosamine (O-GlcNAc) on HDAC4 were investigated in vivo and in vitro by biochemical and cellular assays. RESULTS: We show that the cardio-protective N-terminal proteolytic fragment of HDAC4 is enhanced in vivo in patients with diabetes mellitus and mouse models, as well as in vitro under high-glucose and high-O-GlcNAc conditions. HDAC4-knockout mice develop heart failure in models of type 1 and type 2 diabetes mellitus, whereas wild-type mice do not develop clear signs of heart failure, indicating that HDAC4 protects the diabetic heart. Reexpression of the N-terminal fragment of HDAC4 prevents HDAC4-dependent diabetic cardiomyopathy. Mechanistically, the posttranslational modification of HDAC4 at serine (Ser)-642 by O-GlcNAcylation is an essential step for production of the N-terminal fragment of HDAC4, which was attenuated by Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632. Preventing O-GlcNAcylation at Ser-642 not only entirely precluded production of the N-terminal fragment of HDAC4 but also promoted Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632, pointing to a mutual posttranslational modification cross talk of (cardio-detrimental) phosphorylation at Ser-632 and (cardio-protective) O-GlcNAcylation at Ser-642. CONCLUSIONS: In this study, we found that O-GlcNAcylation of HDAC4 at Ser-642 is cardio-protective in diabetes mellitus and counteracts pathological Ca2+/calmodulin-dependent protein kinase II signaling. We introduce a molecular model explaining how diabetic metabolism possesses important cardio-protective features besides its known detrimental effects. A deeper understanding of the here-described posttranslational modification cross talk may lay the groundwork for the development of specific therapeutic concepts to treat heart failure in the context of diabetes mellitus.
BACKGROUND: Worldwide, diabetes mellitus and heart failure represent frequent comorbidities with high socioeconomic impact and steadily growing incidence, calling for a better understanding of how diabetic metabolism promotes cardiac dysfunction. Paradoxically, some glucose-lowering drugs have been shown to worsen heart failure, raising the question of how glucose mediates protective versus detrimental cardiac signaling. Here, we identified a histone deacetylase 4 (HDAC4) subdomain as a molecular checkpoint of adaptive and maladaptive signaling in the diabetic heart. METHODS: A conditional HDAC4 allele was used to delete HDAC4 specifically in cardiomyocytes (HDAC4-knockout). Mice were subjected to diabetes mellitus either by streptozotocin injections (type 1 diabetes mellitus model) or by crossing into mice carrying a leptin receptor mutation (db/db; type 2 diabetes mellitus model) and monitored for remodeling and cardiac function. Effects of glucose and the posttranslational modification by β-linked N-acetylglucosamine (O-GlcNAc) on HDAC4 were investigated in vivo and in vitro by biochemical and cellular assays. RESULTS: We show that the cardio-protective N-terminal proteolytic fragment of HDAC4 is enhanced in vivo in patients with diabetes mellitus and mouse models, as well as in vitro under high-glucose and high-O-GlcNAc conditions. HDAC4-knockout mice develop heart failure in models of type 1 and type 2 diabetes mellitus, whereas wild-type mice do not develop clear signs of heart failure, indicating that HDAC4 protects the diabetic heart. Reexpression of the N-terminal fragment of HDAC4 prevents HDAC4-dependent diabetic cardiomyopathy. Mechanistically, the posttranslational modification of HDAC4 at serine (Ser)-642 by O-GlcNAcylation is an essential step for production of the N-terminal fragment of HDAC4, which was attenuated by Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632. Preventing O-GlcNAcylation at Ser-642 not only entirely precluded production of the N-terminal fragment of HDAC4 but also promoted Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation at Ser-632, pointing to a mutual posttranslational modification cross talk of (cardio-detrimental) phosphorylation at Ser-632 and (cardio-protective) O-GlcNAcylation at Ser-642. CONCLUSIONS: In this study, we found that O-GlcNAcylation of HDAC4 at Ser-642 is cardio-protective in diabetes mellitus and counteracts pathological Ca2+/calmodulin-dependent protein kinase II signaling. We introduce a molecular model explaining how diabetic metabolism possesses important cardio-protective features besides its known detrimental effects. A deeper understanding of the here-described posttranslational modification cross talk may lay the groundwork for the development of specific therapeutic concepts to treat heart failure in the context of diabetes mellitus.
Entities:
Keywords:
HDAC4; calcium-calmodulin-dependent protein kinase type 2; diabetes mellitus; heart failure
Authors: Shan Lu; Zhandi Liao; Xiyuan Lu; Dörthe M Katschinski; Mark Mercola; Ju Chen; Joan Heller Brown; Jeffery D Molkentin; Julie Bossuyt; Donald M Bers Journal: Circ Res Date: 2020-03-05 Impact factor: 17.367
Authors: Bence Hegyi; Johanna M Borst; Logan R J Bailey; Erin Y Shen; Austen J Lucena; Manuel F Navedo; Julie Bossuyt; Donald M Bers Journal: Basic Res Cardiol Date: 2020-11-25 Impact factor: 17.165
Authors: Olurotimi O Mesubi; Adam G Rokita; Neha Abrol; Yuejin Wu; Biyi Chen; Qinchuan Wang; Jonathan M Granger; Anthony Tucker-Bartley; Elizabeth D Luczak; Kevin R Murphy; Priya Umapathi; Partha S Banerjee; Tatiana N Boronina; Robert N Cole; Lars S Maier; Xander H Wehrens; Joel L Pomerantz; Long-Sheng Song; Rexford S Ahima; Gerald W Hart; Natasha E Zachara; Mark E Anderson Journal: J Clin Invest Date: 2021-01-19 Impact factor: 14.808
Authors: Priya Umapathi; Olurotimi O Mesubi; Partha S Banerjee; Neha Abrol; Qinchuan Wang; Elizabeth D Luczak; Yuejin Wu; Jonathan M Granger; An-Chi Wei; Oscar E Reyes Gaido; Liliana Florea; C Conover Talbot; Gerald W Hart; Natasha E Zachara; Mark E Anderson Journal: Circulation Date: 2021-02-17 Impact factor: 29.690
Authors: Stefanie Maria Werhahn; Julia S Kreusser; Marco Hagenmüller; Jan Beckendorf; Nathalie Diemert; Sophia Hoffmann; Jobst-Hendrik Schultz; Johannes Backs; Matthias Dewenter Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240